Pooja Hingorani Selected Research

Pooja Hingorani Research Topics

Disease

23	Neoplasms (Cancer) 01/2023 - 05/2009
17	Osteosarcoma (Osteogenic Sarcoma) 01/2023 - 05/2009
7	Rhabdomyosarcoma 01/2021 - 09/2009
7	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 09/2009
3	Neoplasm Metastasis (Metastasis) 01/2020 - 05/2009
3	Ewing Sarcoma (Sarcoma, Ewing) 01/2020 - 09/2009
1	Sudden Death 09/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Pinealoma (Pineoblastoma) 01/2021
1	Central Nervous System Neoplasms 01/2021
1	Infections 01/2021
1	Desmoplastic Small Round Cell Tumor 01/2020
1	Glioma (Gliomas) 12/2019
1	Hemangioma (Angioma) 01/2019
1	Neutropenia 01/2019
1	Choriocarcinoma 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Virus Diseases (Viral Diseases) 01/2014
1	Brain Diseases (Brain Disorder) 09/2009
1	Hemorrhagic Cystitis 09/2009

Drug/Important Bio-Agent (IBA)

4	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2020
3	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2020
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2010
3	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022 - 01/2020
2	130-nm albumin-bound paclitaxelIBA 01/2020 - 01/2018
2	dabrafenibIBA 12/2019 - 12/2019
2	Bevacizumab (Avastin)FDA Link 11/2019 - 10/2012
2	Monoclonal AntibodiesIBA 10/2016 - 07/2010
2	Immune Checkpoint InhibitorsIBA 10/2016 - 01/2015
1	copanlisibIBA 01/2023
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2023
1	CytokinesIBA 09/2022
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2022
1	dinutuximabIBA 09/2022
1	Immunotoxins (Immunotoxin)IBA 01/2022
1	trastuzumab deruxtecanIBA 01/2022
1	Matrix Metalloproteinase 14 (MT1-MMP)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Surface Antigens (Surface Antigen)IBA 01/2022
1	Alanine Transaminase (SGPT)IBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	TransferasesIBA 01/2021
1	NucleotidesIBA 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	monomethyl auristatin EIBA 01/2021
1	olaratumabIBA 01/2021
1	Leucine (L-Leucine)FDA Link 01/2021
1	temsirolimus FDA Link 11/2019
1	GlypicansIBA 01/2019
1	EnzymesIBA 01/2019
1	halichondrin BIBA 01/2019
1	CAM 5.2 antigenIBA 01/2019
1	Propranolol (Inderal)FDA LinkGeneric 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	eribulin FDA Link 01/2019
1	AntigensIBA 10/2016
1	Cancer VaccinesIBA 10/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2015
1	LigandsIBA 04/2015
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2015
1	sepantroniumIBA 01/2013
1	Antineoplastic Agents (Antineoplastics)IBA 01/2013
1	SurvivinIBA 01/2013
1	Inhibitor of Apoptosis ProteinsIBA 01/2013
1	Docetaxel (Taxotere)FDA Link 10/2012
1	Gemcitabine FDA Link 10/2012
1	Antiviral Agents (Antivirals)IBA 02/2012
1	Cisplatin (Platino)FDA LinkGeneric 04/2011
1	Cytotoxins (Cytolysins)IBA 04/2011
1	Immunoglobulin G (IgG)IBA 07/2010
1	teprotumumabIBA 07/2010
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 07/2010
1	Sirolimus (Rapamycin)FDA Link 07/2010
1	VaccinesIBA 04/2010
1	Acrolein (Aqualin)IBA 09/2009
1	ProdrugsIBA 09/2009
1	Ifosfamide FDA LinkGeneric 09/2009
1	isophosphamide mustard (IPAM)IBA 09/2009
1	palifosfamide lysineIBA 09/2009
1	Phosphotransferases (Kinase)IBA 05/2009
1	src-Family KinasesIBA 05/2009
1	Dasatinib (BMS 354825)FDA Link 05/2009
1	Dihydrotachysterol (AT 10)IBA 05/2009

Therapy/Procedure

17	Therapeutics 09/2022 - 04/2010
7	Drug Therapy (Chemotherapy) 01/2021 - 04/2010
2	Investigational Therapies (Experimental Therapy) 01/2020 - 01/2018
2	Radiotherapy 11/2019 - 04/2011
2	Immunotherapy 10/2016 - 01/2015
2	Oncolytic Virotherapy 01/2014 - 02/2012
1	Duration of Therapy 12/2019